Synopsis:- Shares declined after a ~3% fall amid regulatory setbacks in Brazil and a cautious brokerage outlook, indicating ~13% downside. Margin pressure persisted with OPM dropping from 27% to 22%, while increasing competition and delayed product entry raised concerns over near-term growth visibility.
The shares of the prominent pharmaceutical company plummeted 3 percent in today’s trading session after a brokerage issued a sell call, following Brazil’s ANVISA rejection of its Semaglutide generic, raising concerns over regulatory setbacks and growth prospects.
With a market capitalization of Rs 1,01,689.85 crore, the shares of Dr Reddy’s Laboratories Ltd were trading at Rs 1,218.40 per share, decreasing around 1.36 percent as compared to the previous closing price of Rs 1,235.20 apiece.
Brokerage Recommendation
Citi has issued a ‘sell’ rating on the pharma stock with a target price of Rs 1,070, which implies a ~13% downside from the current level of Rs 1,235.20. This suggests a cautious stance, indicating near-term risks and valuation concerns despite the positive rating.
Dr. Reddy’s faces a setback after Brazil’s ANVISA rejected its Semaglutide generic, Embeltah, citing gaps in demonstrating efficacy, safety, and quality. This delays its entry into a key emerging market, potentially impacting near-term growth expectations as regulatory hurdles remain a critical factor in complex generic launches.
As per the brokerage, the rejection also limits Dr. Reddy’s participation in the initial wave of Semaglutide launches in Brazil, where competition is intensifying with around 16 applications under review. Missing early entry could result in lost market share opportunities and reduced pricing power in a highly competitive landscape.
Additionally, Apotex’s securing tentative approval in the US signals a potential competitive edge in the Canadian market. This development may further pressure Dr. Reddy’s positioning globally, as peers advance faster in key markets, highlighting execution risks and the importance of timely regulatory clearances in specialty generics.
The company reported modest topline growth, with revenue rising 4% from Rs 8,381 crore to Rs 8,753 crore, indicating stable demand. However, profitability declined, with net profit falling 15% from Rs 1,404 crore to Rs 1,190 crore, suggesting margin pressure, higher costs, or adverse product mix impacting overall earnings despite revenue growth.
From Dec 2024 to Dec 2025, operating profit showed volatility, declining from Rs 2,273 crore to Rs 2,174 crore in Jun 2025 before further declining to Rs 1,888 crore. Meanwhile, OPM steadily contracted from 27% to 22%, indicating margin pressure, likely due to rising costs or an unfavorable product mix impacting overall operating efficiency.
Dr. Reddy’s Laboratories Ltd is a leading global pharmaceutical company known for its strong presence in generics, APIs, and specialty medicines. With operations across key markets like the US, India, and emerging economies, the company focuses on affordable healthcare, innovation, and expanding its portfolio of complex and specialty products.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Why Are Dr. Reddy’s Laboratories Shares Facing Pressure on Result Day? appeared first on Trade Brains.